The global tyrosine kinase market is anticipated to witness a considerable CAGR of during the forecast period (2020-2026). The rising prevalence of cancer across the globe along with the growing R&D of new tyrosine kinase inhibitors is a key factor anticipated to drive the growth of the global tyrosine kinase market. According to the World Health Organization (WHO), cancer is the second leading cause of mortality across the globe which is responsible for around 9.6 million mortalities and accounted for 18.1 million new cases in 2018, globally. 1 in 5 men and 1 in 6 women, across the globe, develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease.
To Request a Sample of our Report on Global Tyrosine Kinase Market: https://www.omrglobal.com/request-sample/tyrosine-kinase-market
The tyrosine kinase inhibitors are given to the patients in order to stop the growth of cancer cells. Therefore, the high prevalence of different kinds of cancers is anticipated to create the demand for these drugs, which in turn is driving the growth of the tyrosine kinase inhibitor drugs across the globe.
GlaxoSmithKline PLC, Novartis International AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Eurofarma Laboratórios S/A, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, and so on are the key companies operating in the tyrosine kinase market across the globe. The major players of the tyrosine kinase market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the global tyrosine kinase market.
(Get 15% Discount on Buying this Report)
A full Report of Global Tyrosine Kinase Market is Available at: https://www.omrglobal.com/industry-reports/tyrosine-kinase-market
Recent Development in the Market
In May 2018, Pfizer, Inc. had announced the US Food and Drug Administration (FDA) approval for the breakthrough therapy designation for XALKORI (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. In addition, the FDA had granted breakthrough therapy designation for XALKORI for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.
Global Tyrosine Kinase Market Segmentation
- BCR-ABL Tyrosine Kinase Inhibitor
- Epidermal Growth Factor Receptor (EGFR)
- Vascular Endothelial Growth Factor Receptor (VEGFR)
- Anaplastic Lymphoma Kinase (ALK)
- Chronic Myeloid Leukemia (CML)
- Lung Cancer
- Breast Cancer
- Renal Cell Cancer
- United States
- Rest of Europe
- Rest oF APAC
Rest of The World
- ARIAD Pharmaceuticals, Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Eurofarma Laboratórios S/A
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson and Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Puma Biotechnology
- Sanofi S.A.
- Wyeth, LLC
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/tyrosine-kinase-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit Orion Market Research
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404